Incyte (INCY) vs Medpace (MEDP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Incyte (INCY) has outperformed Medpace (MEDP) over the past year, gaining 32.1% versus a gain of 13.5%. Over five years, MEDP leads with a +222.2% price change compared with +72.0% for INCY. Incyte is the larger company by market cap ($22.86 billion vs $17.08 billion), about 1.3 times the size.
On valuation, Incyte trades at a lower forward P/E (12.9x vs 31.7x for Medpace). Incyte converts more of its revenue into profit, with a net margin of 25.0% versus 17.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INCY | MEDP |
|---|---|---|
| Share price | $112.79 | $612.05 |
| Market cap | $22.86B | $17.08B |
| 1-day change | +0.04% | +1.55% |
| YTD return | +14.15% | +7.31% |
| 1-year return | +32.06% | +13.50% |
| 5-year return | +71.98% | +222.16% |
| P/E ratio (TTM) | 14.37 | 35.94 |
| Forward P/E | 12.89 | 31.69 |
| EPS (TTM) | $7.85 | $17.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.14B | $2.53B |
| Revenue growth (YoY) | +21.22% | +19.97% |
| Net income (latest FY) | $1.29B | $451.12M |
| Gross margin | 92.76% | — |
| Operating margin | 29.46% | 21.14% |
| Net margin | 25.03% | 17.83% |
| 52-week high | $132.60 | $677.90 |
| 52-week low | $82.82 | $373.00 |
| Distance from 52-week high | -14.94% | -9.71% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +14.49% | -3.30% |
| Average volume | 1.63M | 272.38K |
| Shares outstanding | 202.70M | 27.91M |
| Employees | 2,844 | 6,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INCY has outperformed MEDP by 18.6 percentage points over the past year.
- Medpace trades at a higher earnings multiple (35.9x vs 14.4x trailing P/E).
- Incyte is more profitable, keeping 25.0 cents of every revenue dollar as net income versus 17.8 cents for Medpace.
About Incyte
INCY stock →Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 2,844 employees
About Medpace
MEDP stock →Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 6,500 employees
INCY vs MEDP FAQ
Which is bigger, Incyte or Medpace?
Incyte (INCY) is larger, with a market capitalization of $22.86B compared with $17.08B for Medpace (MEDP).
Which stock has performed better over the past year, INCY or MEDP?
INCY returned +32.06% over the past 12 months, compared with +13.50% for MEDP (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, INCY or MEDP?
INCY has the lower trailing P/E at 14.4, versus 35.9 for MEDP. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Incyte and Medpace in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.